cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Adverum Biotechnologies Inc
2 own
6 watching
Current Price
$7.62
$-0.47
(-5.81%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
147.84M
52-Week High
52-Week High
29.70000
52-Week Low
52-Week Low
7.24000
Average Volume
Average Volume
0.11M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization147.84M
icon52-Week High29.70000
icon52-Week Low7.24000
iconAverage Volume0.11M
iconDividend Yield--
iconP/E Ratio--
What does the Adverum Biotechnologies Inc do?
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Read More
How much money does Adverum Biotechnologies Inc make?
News & Events about Adverum Biotechnologies Inc.
Globe Newswire
1 year ago
Adverum has granted Ray Therapeutics a non-exclusive, royalty-bearing license for the use of Adverums proprietary intravitreal AAV.7m8 vector capsid together with RayTxs RTx-015 assetREDWOOD CITY, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-...
Globe Newswire
1 year ago
- Wet age-related macular degeneration (wet AMD) is a bilateral disease and incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in the primary eye - - Staggered administration of Ixo-vec in non-human primates (NHPs) showed peak ...
Ticker Report
1 year ago
LADENBURG THALM/SH SH assumed coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM Get Rating) in a research report report published on Tuesday , The Fly reports. The brokerage issued a buy rating and a $2.00 price objective on the biotechnology companys stock. Several other ...
Ticker Report
1 year ago
LADENBURG THALM/SH SH started coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM Get Rating) in a research note released on Tuesday , The Fly reports. The firm issued a buy rating and a $2.00 price target on the biotechnology companys stock. A number of other research analysts...
Ticker Report
1 year ago
Adverum Biotechnologies, Inc. (NASDAQ:ADVM Get Rating) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,140,000 shares, a decline of 11.9% from the November 30th total of 2,430,000 shares. ...
Frequently Asked Questions
Frequently Asked Questions
What is Adverum Biotechnologies Inc share price today?
plus_minus_icon
Can Indians buy Adverum Biotechnologies Inc shares?
plus_minus_icon
How can I buy Adverum Biotechnologies Inc shares from India?
plus_minus_icon
Can Fractional shares of Adverum Biotechnologies Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Adverum Biotechnologies Inc stocks?
plus_minus_icon
What is today’s traded volume of Adverum Biotechnologies Inc?
plus_minus_icon
What is today’s market capitalisation of Adverum Biotechnologies Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Adverum Biotechnologies Inc?
plus_minus_icon
What percentage is Adverum Biotechnologies Inc down from its 52-Week High?
plus_minus_icon
What percentage is Adverum Biotechnologies Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$7.62
$-0.47
(-5.81%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00